The US pharma company MSD and MPP (Medicines Patent Pool) entered the voluntary licensing agreement that will facilitate the distribution and affordable access to molnupiravir in 105 low and middle-income countries.
Under such agreement, MPP will be able to further sub-license the production of the drug to multiple manufacturers in the signatory countries, thus ensuring a steady supply in the different regions of the world. MPP is a UN-backed organisation that negotiates public-health related licenses with patent holders, in order to sub-license necessary drugs to generic manufacturers under fair and reasonable terms.
In India, MSD has signed a voluntary licensing agreement with eight different providers, allowing a wide coverage for the production of the drug in the country and beyond.
- Publication date
- 2 November 2021